• What are Therapeutic Market Outlooks?
• Available Reports
• Pricing and Deliverables
• TMO Sample Pages

TMO Home

Report Overview

Table of Contents

Tables and Figures

TMO Overview - Lipid Modulating Agents

Dyslipidemia is a disease characterized by abnormal levels of lipids in the circulatory system. The most common forms of dyslipidemia involve elevation of total serum cholesterol (TSC), elevation of low-density lipoprotein (LDL), elevation of triglycerides (TG), and a reduction of high-density lipoprotein (HDL). Lipid modulating agents target varying aspects of dyslipidemia, and are often chosen as treatment options. Thanks to aggressive screening and treatment, the market for lipid modulating agents will continue to see strong volume growth. AVOS predicts that the number of individuals suffering from dyslipidemia, regardless of diagnosis, will increase from 112.4 million in 2008 to 117.7 million in 2013. Despite this significant volume growth, AVOS predicts that a general lack of innovation will cause generics - among them, atorvastatin, launching in 2010 - to capture over 50% of the lipid modulating agent market by 2013. As a result of the impact of generic blockbusters during the forecast period, and robust growth among HDL-raising therapies, the market for lipid modulating agents is projected to increase from $19.8 billion in 2008 to $24.4 billion in 2013 after peaking in 2010 at $24.6 billion.

AVOS Life Sciences' TMO Lipid Modulating Agents report addresses each key aspect of a rigorous, disease-based market analysis:

Market Size & Expected Growth	In-depth epidemiological analysis and modeling Detailed review of current and projected treatment landscape at a class level
Treatment Cascade	Consideration of the treatment algorithms for primary indication Impact of manipulating treatment cascade through promotional and other initiatives
Drug Class Characteristics	Fundamentals: safety, efficacy, side effects, onset of action, duration, etc. Developer strengths and weaknesses (technology, marketing, sales, etc.)
Competitive Landscape	Comprehensive competitve pipeline overview at a drug level In-depth review of all major competing treatment mechanisms and drug classes
Pricing & Reimbursement Landscape	Where appropriate, price elaticity calculations based on payer and provider interviews Evaluation of reimbursement landscape for indication and similar projects
Class Position Effects	Detailed research and analysis for first-in-class products Scenario analysis of entrants into markets with existing products
Projected Market Share Shifts	Sophisticated uptake models (historical view, firm and product attributes) Predictions for shifts resulting from the use of several marketing levers

Key findings in AVOS's TMO Lipid Modulating Agents report include:

• Strong double digit sector-wide unit volume growth: Sector-wide prescription volume growth remains strong, growing 13.5% in 2005 and 13.3% in 2006. We expect the dyslipidemia market to continue expanding over the next six years propelled by...
• Lack of innovation will allow generics to capture over 50% of the market by 2013: Most new branded drugs expected to enter the market are...
• We predict -13% CAGR for Lipitor TRx (total prescriptions) between 2006 and 2010 due to continued decline in new prescription volumes: Lipitor's 2006 TRx market share is down six points to 35% and is on track to drop six more points...
• Long-term outlook for Crestor is positive: STELLAR, ASTEROID and METEOR studies have helped dispel concerns about Crestor's safety and established its efficacy profile. Despite these studies, AVOS research found...
• HDL is the new growth driver: Demographic analysis shows 33 million addressable patients with low HDL in 2006. Only 4% of this population has been treated with drug therapy to raise HDL. We predict that...

AVOS's TMO Lipid Modulating Agents report will prove to be a valuable tool for individuals in business development, marketing and analytics, and R&D who require balanced and authoritative insight into the growing and rapidly changing market for drugs to treat dyslipidemia.